Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Author index

Page Path
HOME > Browse > Author index
Search
Choon Hee Chung  (Chung CH) 9 Articles
Basic Research
DWN12088, A Prolyl-tRNA Synthetase Inhibitor, Alleviates Hepatic Injury in Nonalcoholic Steatohepatitis
Dong-Keon Lee, Su Ho Jo, Eun Soo Lee, Kyung Bong Ha, Na Won Park, Deok-Hoon Kong, Sang-In Park, Joon Seok Park, Choon Hee Chung
Diabetes Metab J. 2024;48(1):97-111.   Published online January 3, 2024
DOI: https://doi.org/10.4093/dmj.2022.0367
  • 1,723 View
  • 179 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Nonalcoholic steatohepatitis (NASH) is a liver disease caused by obesity that leads to hepatic lipoapoptosis, resulting in fibrosis and cirrhosis. However, the mechanism underlying NASH is largely unknown, and there is currently no effective therapeutic agent against it. DWN12088, an agent used for treating idiopathic pulmonary fibrosis, is a selective prolyl-tRNA synthetase (PRS) inhibitor that suppresses the synthesis of collagen. However, the mechanism underlying the hepatoprotective effect of DWN12088 is not clear. Therefore, we investigated the role of DWN12088 in NASH progression.
Methods
Mice were fed a chow diet or methionine-choline deficient (MCD)-diet, which was administered with DWN12088 or saline by oral gavage for 6 weeks. The effects of DWN12088 on NASH were evaluated by pathophysiological examinations, such as real-time quantitative reverse transcription polymerase chain reaction, immunoblotting, biochemical analysis, and immunohistochemistry. Molecular and cellular mechanisms of hepatic injury were assessed by in vitro cell culture.
Results
DWN12088 attenuated palmitic acid (PA)-induced lipid accumulation and lipoapoptosis by downregulating the Rho-kinase (ROCK)/AMP-activated protein kinase (AMPK)/sterol regulatory element-binding protein-1c (SREBP-1c) and protein kinase R-like endoplasmic reticulum kinase (PERK)/α subunit of eukaryotic initiation factor 2 (eIF2α)/activating transcription factor 4 (ATF4)/C/EBP-homologous protein (CHOP) signaling cascades. PA increased but DWN12088 inhibited the phosphorylation of nuclear factor-κB (NF-κB) p65 (Ser536, Ser276) and the expression of proinflammatory genes. Moreover, the DWN12088 inhibited transforming growth factor β (TGFβ)-induced pro-fibrotic gene expression by suppressing TGFβ receptor 1 (TGFβR1)/Smad2/3 and TGFβR1/glutamyl-prolyl-tRNA synthetase (EPRS)/signal transducer and activator of transcription 6 (STAT6) axis signaling. In the case of MCD-diet-induced NASH, DWN12088 reduced hepatic steatosis, inflammation, and lipoapoptosis and prevented the progression of fibrosis.
Conclusion
Our findings provide new insights about DWN12088, namely that it plays an important role in the overall improvement of NASH. Hence, DWN12088 shows great potential to be developed as a new integrated therapeutic agent for NASH.
Drug Regimen
Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension
Jun Sung Moon, Il Rae Park, Hae Jin Kim, Choon Hee Chung, Kyu Chang Won, Kyung Ah Han, Cheol-Young Park, Jong Chul Won, Dong Jun Kim, Gwan Pyo Koh, Eun Sook Kim, Jae Myung Yu, Eun-Gyoung Hong, Chang Beom Lee, Kun-Ho Yoon
Diabetes Metab J. 2023;47(6):808-817.   Published online September 26, 2023
DOI: https://doi.org/10.4093/dmj.2022.0387
  • 2,556 View
  • 279 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
This study investigates the long-term efficacy and safety of evogliptin add-on therapy in patients with inadequately controlled type 2 diabetes mellitus (T2DM) previously received dapagliflozin and metformin (DAPA/MET) combination.
Methods
In this multicenter randomized placebo-controlled phase 3 trial, patients with glycosylated hemoglobin (HbA1c) levels 7.0% to 10.5% (n=283) previously used DAPA 10 mg plus MET (≥1,000 mg) were randomly assigned to the evogliptin 5 mg once daily or placebo group (1:1). The primary endpoint was the difference in the HbA1c level from baseline at week 24, and exploratory endpoints included the efficacy and safety of evogliptin over 52 weeks (trial registration: ClinicalTrials.gov NCT04170998).
Results
Evogliptin add-on to DAPA/MET therapy was superior in HbA1c reduction compared to placebo at weeks 24 and 52 (least square [LS] mean difference, –0.65% and –0.55%; 95% confidence interval [CI], –0.79 to –0.51 and –0.71 to –0.39; P<0.0001). The proportion of patients achieving HbA1c <7% was higher in the triple combination group at week 52 (32.14% vs. 8.51% in placebo; odds ratio, 5.62; P<0.0001). Evogliptin significantly reduced the fasting glucose levels and mean daily glucose levels with improvement in homeostatic model assessment of β-cell function (LS mean difference, 9.04; 95% CI, 1.86 to 16.21; P=0.0138). Adverse events were similar between the groups, and no serious adverse drug reactions were reported in the evogliptin group.
Conclusion
Long-term triple combination with evogliptin added to DAPA/MET showed superior HbA1c reduction and glycemic control compared to placebo at 52 weeks and was well tolerated.
Basic Research
Beneficial Effects of a Curcumin Derivative and Transforming Growth Factor-β Receptor I Inhibitor Combination on Nonalcoholic Steatohepatitis
Kyung Bong Ha, Eun Soo Lee, Na Won Park, Su Ho Jo, Soyeon Shim, Dae-Kee Kim, Chan Mug Ahn, Choon Hee Chung
Diabetes Metab J. 2023;47(4):500-513.   Published online April 25, 2023
DOI: https://doi.org/10.4093/dmj.2022.0110
  • 2,144 View
  • 144 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Curcumin 2005-8 (Cur5-8), a derivative of curcumin, improves fatty liver disease via AMP-activated protein kinase activation and autophagy regulation. EW-7197 (vactosertib) is a small molecule inhibitor of transforming growth factor β (TGF-β) receptor I and may scavenge reactive oxygen species and ameliorate fibrosis through the SMAD2/3 canonical pathway. This study aimed to determine whether co-administering these two drugs having different mechanisms is beneficial.
Methods
Hepatocellular fibrosis was induced in mouse hepatocytes (alpha mouse liver 12 [AML12]) and human hepatic stellate cells (LX-2) using TGF-β (2 ng/mL). The cells were then treated with Cur5-8 (1 μM), EW-7197 (0.5 μM), or both. In animal experiments were also conducted during which, methionine-choline deficient diet, Cur5-8 (100 mg/kg), and EW-7197 (20 mg/kg) were administered orally to 8-week-old C57BL/6J mice for 6 weeks.
Results
TGF-β-induced cell morphological changes were improved by EW-7197, and lipid accumulation was restored on the administration of EW-7197 in combination with Cur5-8. In a nonalcoholic steatohepatitis (NASH)-induced mouse model, 6 weeks of EW-7197 and Cur5-8 co-administration alleviated liver fibrosis and improved the nonalcoholic fatty liver disease (NAFLD) activity score.
Conclusion
Co-administering Cur5-8 and EW-7197 to NASH-induced mice and fibrotic hepatocytes reduced liver fibrosis and steatohepatitis while maintaining the advantages of both drugs. This is the first study to show the effect of the drug combination against NASH and NAFLD. Similar effects in other animal models will confirm its potential as a new therapeutic agent.
Drug/Regimen
A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus
Bo-Yeon Kim, Hyuk-Sang Kwon, Suk Kyeong Kim, Jung-Hyun Noh, Cheol-Young Park, Hyeong-Kyu Park, Kee-Ho Song, Jong Chul Won, Jae Myung Yu, Mi Young Lee, Jae Hyuk Lee, Soo Lim, Sung Wan Chun, In-Kyung Jeong, Choon Hee Chung, Seung Jin Han, Hee-Seok Kim, Ju-Young Min, Sungrae Kim
Diabetes Metab J. 2022;46(6):855-865.   Published online March 8, 2022
DOI: https://doi.org/10.4093/dmj.2021.0264
  • 6,675 View
  • 296 Download
  • 6 Web of Science
  • 7 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
Thiazolidinediones (TZDs) have been associated with various safety concerns including weight gain, bladder cancer, and congestive heart failure (CHF). This study evaluated the efficacy and safety of lobeglitazone, a novel TZD in patients with type 2 diabetes mellitus (T2DM) in real practice.
Methods
In this non-interventional, multi-center, retrospective, and observational study conducted at 15 tertiary or secondary referral hospitals in Korea, a total of 2,228 patients with T2DM who received lobeglitazone 0.5 mg for more than 1 year were enrolled.
Results
Overall adverse events (AEs) occurred in 381 patients (17.10%) including edema in 1.97% (n=44). Cerebrovascular and cardiovascular diseases were identified in 0.81% (n=18) and 0.81% (n=18), respectively. One case of CHF was reported as an AE. Edema occurred in 1.97% (n=44) of patients. Hypoglycemia occurred in 2.47% (n=55) of patients. Fracture occurred in 1.17% (n=26) of all patients. Lobeglitazone significantly decreased HbA1c level, resulting in a mean treatment difference of -1.05%± 1.35% (P<0.001), and decreased total cholesterol, triglyceride, and low-density lipoprotein cholesterol. However, it increased high-density lipoprotein cholesterol, regardless of statin administration. The patients who received lobeglitazone 0.5 mg showed an apparent reduction in glycosylated hemoglobin (HbA1c) from baseline during the first 6 months of treatment. The HbA1c levels remained stable between months 6 and 42.
Conclusion
Lobeglitazone has long-term safety profile, good glycemic-lowering effect and long-term durability of glycemic control in real-world clinical settings.

Citations

Citations to this article as recorded by  
  • Efficacy and safety of novel thiazolidinedione lobeglitazone for managing type-2 diabetes a meta-analysis
    Deep Dutta, Saptarshi Bhattacharya, Manoj Kumar, Priyankar K. Datta, Ritin Mohindra, Meha Sharma
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102697.     CrossRef
  • Efficacy and safety of lobeglitazone, a new Thiazolidinedione, as compared to the standard of care in type 2 diabetes mellitus: A systematic review and meta-analysis
    Shashank R. Joshi, Saibal Das, Suja Xaviar, Shambo Samrat Samajdar, Indranil Saha, Sougata Sarkar, Shatavisa Mukherjee, Santanu Kumar Tripathi, Jyotirmoy Pal, Nandini Chatterjee
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102703.     CrossRef
  • Will lobeglitazone rival pioglitazone? A systematic review and critical appraisal
    Kalyan Kumar Gangopadhyay, Awadhesh Kumar Singh
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(4): 102747.     CrossRef
  • Lobeglitazone

    Reactions Weekly.2023; 1948(1): 262.     CrossRef
  • Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study
    Joonsang Yoo, Jimin Jeon, Minyoul Baik, Jinkwon Kim
    Cardiovascular Diabetology.2023;[Epub]     CrossRef
  • Lobeglitazone and Its Therapeutic Benefits: A Review
    Balamurugan M, Sarumathy S, Robinson R
    Cureus.2023;[Epub]     CrossRef
  • Oldies but Goodies: Thiazolidinedione as an Insulin Sensitizer with Cardioprotection
    Eun-Hee Cho
    Diabetes & Metabolism Journal.2022; 46(6): 827.     CrossRef
Clinical Diabetes & Therapeutics
Effects of Lobeglitazone, a Novel Thiazolidinedione, on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus over 52 Weeks
Soo Lim, Kyoung Min Kim, Sin Gon Kim, Doo Man Kim, Jeong-Taek Woo, Choon Hee Chung, Kyung Soo Ko, Jeong Hyun Park, Yongsoo Park, Sang Jin Kim, Hak Chul Jang, Dong Seop Choi
Diabetes Metab J. 2017;41(5):377-385.   Published online October 24, 2017
DOI: https://doi.org/10.4093/dmj.2017.41.5.377
  • 4,243 View
  • 42 Download
  • 19 Web of Science
  • 20 Crossref
AbstractAbstract PDFPubReader   
Background

The aim of this multicenter, randomized, double-blind study was to examine the effect of lobeglitazone, a novel thiazolidinedione, on the changes in bone mineral density (BMD) in patients with type 2 diabetes mellitus.

Methods

A 24-week, double-blinded phase was followed by a 28-week, open-label phase, in which the placebo group also started to receive lobeglitazone. A total of 170 patients aged 34 to 76 years were randomly assigned in a 2:1 ratio to receive lobeglitazone 0.5 mg or a matching placebo orally, once daily. BMD was assessed using dual-energy X-ray absorptiometry at week 24 and at the end of the study (week 52).

Results

During the double-blinded phase, the femur neck BMD showed decreasing patterns in both groups, without statistical significance (−0.85%±0.36% and −0.78%±0.46% in the lobeglitazone and placebo groups, respectively). The treatment difference between the groups was 0.07%, which was also not statistically significant. Further, minimal, nonsignificant decreases were observed in both groups in the total hip BMD compared to values at baseline, and these differences also did not significantly differ between the groups. During the open-label phase, the BMD was further decreased, but not significantly, by −0.32% at the femur neck and by −0.60% at the total hip in the lobeglitazone group, and these changes did not significantly differ compared with the original placebo group switched to lobeglitazone.

Conclusion

Our results indicate that treatment with lobeglitazone 0.5 mg over 52 weeks showed no detrimental effect on the BMD compared to the placebo.

Citations

Citations to this article as recorded by  
  • Efficacy and safety of novel thiazolidinedione lobeglitazone for managing type-2 diabetes a meta-analysis
    Deep Dutta, Saptarshi Bhattacharya, Manoj Kumar, Priyankar K. Datta, Ritin Mohindra, Meha Sharma
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102697.     CrossRef
  • Efficacy and safety of lobeglitazone, a new Thiazolidinedione, as compared to the standard of care in type 2 diabetes mellitus: A systematic review and meta-analysis
    Shashank R. Joshi, Saibal Das, Suja Xaviar, Shambo Samrat Samajdar, Indranil Saha, Sougata Sarkar, Shatavisa Mukherjee, Santanu Kumar Tripathi, Jyotirmoy Pal, Nandini Chatterjee
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102703.     CrossRef
  • The benefits of adipocyte metabolism in bone health and regeneration
    Lisa-Marie Burkhardt, Christian H. Bucher, Julia Löffler, Charlotte Rinne, Georg N. Duda, Sven Geissler, Tim J. Schulz, Katharina Schmidt-Bleek
    Frontiers in Cell and Developmental Biology.2023;[Epub]     CrossRef
  • Will lobeglitazone rival pioglitazone? A systematic review and critical appraisal
    Kalyan Kumar Gangopadhyay, Awadhesh Kumar Singh
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(4): 102747.     CrossRef
  • Comparison of therapeutic efficacy and safety of sitagliptin, dapagliflozin, or lobeglitazone adjunct therapy in patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea and metformin: Third agent study
    Jun Hwa Hong, Jun Sung Moon, Kayeon Seong, Soo Lim
    Diabetes Research and Clinical Practice.2023; 203: 110872.     CrossRef
  • Bone Mineral Density Evaluation Among Type 2 Diabetic Patients in Rural Haryana, India: An Analytical Cross-Sectional Study
    Nitish Khandelwal, Surbhi Rajauria, Siddhesh Pandurang Kanjalkar, Omkar Shivaji Chavanke, Sanjay Rai
    Cureus.2023;[Epub]     CrossRef
  • Lobeglitazone and Its Therapeutic Benefits: A Review
    Balamurugan M, Sarumathy S, Robinson R
    Cureus.2023;[Epub]     CrossRef
  • A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study
    Soree Ryang, Sang Soo Kim, Ji Cheol Bae, Ji Min Han, Su Kyoung Kwon, Young Il Kim, Il Seong Nam‐Goong, Eun Sook Kim, Mi‐kyung Kim, Chang Won Lee, Soyeon Yoo, Gwanpyo Koh, Min Jeong Kwon, Jeong Hyun Park, In Joo Kim
    Diabetes, Obesity and Metabolism.2022; 24(9): 1800.     CrossRef
  • A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus
    Bo-Yeon Kim, Hyuk-Sang Kwon, Suk Kyeong Kim, Jung-Hyun Noh, Cheol-Young Park, Hyeong-Kyu Park, Kee-Ho Song, Jong Chul Won, Jae Myung Yu, Mi Young Lee, Jae Hyuk Lee, Soo Lim, Sung Wan Chun, In-Kyung Jeong, Choon Hee Chung, Seung Jin Han, Hee-Seok Kim, Ju-Y
    Diabetes & Metabolism Journal.2022; 46(6): 855.     CrossRef
  • Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
    Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
    Diabetes Therapy.2021; 12(1): 171.     CrossRef
  • Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus
    Jaehyun Bae, Taegyun Park, Hyeyoung Kim, Minyoung Lee, Bong-Soo Cha
    Diabetes & Metabolism Journal.2021; 45(3): 326.     CrossRef
  • Effect of lobeglitazone on motor function in rat model of Parkinson’s disease with diabetes co-morbidity
    Kambiz Hassanzadeh, Arman Rahimmi, Mohammad Raman Moloudi, Rita Maccarone, Massimo Corbo, Esmael Izadpanah, Marco Feligioni
    Brain Research Bulletin.2021; 173: 184.     CrossRef
  • Recent Perspective on Thiazolidinedione
    Won Jun Kim
    The Journal of Korean Diabetes.2021; 22(2): 97.     CrossRef
  • Use of in vitro bone models to screen for altered bone metabolism, osteopathies, and fracture healing: challenges of complex models
    Sabrina Ehnert, Helen Rinderknecht, Romina H. Aspera-Werz, Victor Häussling, Andreas K. Nussler
    Archives of Toxicology.2020; 94(12): 3937.     CrossRef
  • Update on: effects of anti-diabetic drugs on bone metabolism
    Guillaume Mabilleau, Béatrice Bouvard
    Expert Review of Endocrinology & Metabolism.2020; 15(6): 415.     CrossRef
  • The use of metformin, insulin, sulphonylureas, and thiazolidinediones and the risk of fracture: Systematic review and meta‐analysis of observational studies
    Khemayanto Hidayat, Xuan Du, Meng‐Jiao Wu, Bi‐Min Shi
    Obesity Reviews.2019; 20(10): 1494.     CrossRef
  • Diabetes pharmacotherapy and effects on the musculoskeletal system
    Evangelia Kalaitzoglou, John L. Fowlkes, Iuliana Popescu, Kathryn M. Thrailkill
    Diabetes/Metabolism Research and Reviews.2019;[Epub]     CrossRef
  • Morin Exerts Anti‐Arthritic Effects by Attenuating Synovial Angiogenesis via Activation of Peroxisome Proliferator Activated Receptor‐γ
    Mengfan Yue, Ni Zeng, Yufeng Xia, Zhifeng Wei, Yue Dai
    Molecular Nutrition & Food Research.2018;[Epub]     CrossRef
  • The effects of diabetes therapy on bone: A clinical perspective
    Karim G. Kheniser, Carmen M. Polanco Santos, Sangeeta R. Kashyap
    Journal of Diabetes and its Complications.2018; 32(7): 713.     CrossRef
  • Changes in the Bone Mineral Density of Femur Neck and Total Hip Over a 52-Week Treatment with Lobeglitazone
    Da Young Lee, Ji A Seo
    Diabetes & Metabolism Journal.2017; 41(5): 374.     CrossRef
Obesity and Metabolic Syndrome
Relationship between Regional Body Fat Distribution and Diabetes Mellitus: 2008 to 2010 Korean National Health and Nutrition Examination Surveys
Soo In Choi, Dawn Chung, Jung Soo Lim, Mi Young Lee, Jang Yel Shin, Choon Hee Chung, Ji Hye Huh
Diabetes Metab J. 2017;41(1):51-59.   Published online December 21, 2016
DOI: https://doi.org/10.4093/dmj.2017.41.1.51
  • 4,151 View
  • 42 Download
  • 35 Web of Science
  • 36 Crossref
AbstractAbstract PDFPubReader   
Background

The aim of this study was to investigate the association between regional body fat distribution, especially leg fat mass, and the prevalence of diabetes mellitus (DM) in adult populations.

Methods

A total of 3,181 men and 3,827 postmenopausal women aged 50 years or older were analyzed based on Korea National Health and Nutrition Examination Surveys (2008 to 2010). Body compositions including muscle mass and regional fat mass were measured using dual-energy X-ray absorptiometry.

Results

The odds ratios (ORs) for DM was higher with increasing truncal fat mass and arm fat mass, while it was lower with increasing leg fat mass. In a partial correlation analysis adjusted for age, leg fat mass was negatively associated with glycosylated hemoglobin in both sexes and fasting glucose in women. Leg fat mass was positively correlated with appendicular skeletal muscle mass and homeostasis model assessment of β cell. In addition, after adjusting for confounding factors, the OR for DM decreased gradually with increasing leg fat mass quartiles in both genders. When we subdivided the participants into four groups based on the median values of leg fat mass and leg muscle mass, higher leg fat mass significantly lowered the risk of DM even though they have smaller leg muscle mass in both genders (P<0.001).

Conclusion

The relationship between fat mass and the prevalence of DM is different according to regional body fat distribution. Higher leg fat mass was associated with a lower risk of DM in Korean populations. Maintaining leg fat mass may be important in preventing impaired glucose tolerance.

Citations

Citations to this article as recorded by  
  • Effects of chromium supplementation on body composition in patients with type 2 diabetes: A dose-response systematic review and meta-analysis of randomized controlled trials
    Mahdi Vajdi, Mahsa khajeh, Ehsan Safaei, Seyedehelham Moeinolsadat, Samin Mousavi, Hooria Seyedhosseini-Ghaheh, Mahdieh Abbasalizad-Farhangi, Gholamreza Askari
    Journal of Trace Elements in Medicine and Biology.2024; 81: 127338.     CrossRef
  • Connections between body composition and dysregulation of islet α- and β-cells in type 2 diabetes
    Jia-xi Miao, Jia-ping Xu, Rui Wang, Yu-xian Xu, Feng Xu, Chun-hua Wang, Chao Yu, Dong-mei Zhang, Jian-bin Su
    Diabetology & Metabolic Syndrome.2024;[Epub]     CrossRef
  • Anthropometric and DXA-derived measures of body composition in relation to pre-diabetes among adults
    Anwar Mohammad, Ali H. Ziyab, Talal Mohammad
    BMJ Open Diabetes Research & Care.2023; 11(5): e003412.     CrossRef
  • A cohort study on the predictive capability of body composition for diabetes mellitus using machine learning
    Mohammad Ali Nematollahi, Amir Askarinejad, Arefeh Asadollahi, Mehdi Bazrafshan, Shirin Sarejloo, Mana Moghadami, Sarvin Sasannia, Mojtaba Farjam, Reza Homayounfar, Babak Pezeshki, Mitra Amini, Mohamad Roshanzamir, Roohallah Alizadehsani, Hanieh Bazrafsha
    Journal of Diabetes & Metabolic Disorders.2023;[Epub]     CrossRef
  • Which is the best diet to reduce cardiometabolic risk: dietary counseling or home-delivered diet?
    Feray Çağiran Yilmaz, Aysun Atilgan, Günay Saka
    Food & Nutrition Research.2023;[Epub]     CrossRef
  • Sedentary lifestyle and body composition in type 2 diabetes
    Dan-dan Li, Yang Yang, Zi-yi Gao, Li-hua Zhao, Xue Yang, Feng Xu, Chao Yu, Xiu-lin Zhang, Xue-qin Wang, Li-hua Wang, Jian-bin Su
    Diabetology & Metabolic Syndrome.2022;[Epub]     CrossRef
  • Impaired Lung Function and Lung Cancer Incidence: A Nationwide Population-Based Cohort Study
    Hye Seon Kang, Yong-Moon Park, Seung-Hyun Ko, Seung Hoon Kim, Shin Young Kim, Chi Hong Kim, Kyungdo Han, Sung Kyoung Kim
    Journal of Clinical Medicine.2022; 11(4): 1077.     CrossRef
  • Association between lung function and the risk of atrial fibrillation in a nationwide population cohort study
    Su Nam Lee, Seung-Hyun Ko, Sung-Ho Her, Kyungdo Han, Donggyu Moon, Sung Kyoung Kim, Ki-Dong Yoo, Yu-Bae Ahn
    Scientific Reports.2022;[Epub]     CrossRef
  • Is imaging-based muscle quantity associated with risk of diabetes? A meta-analysis of cohort studies
    Shanhu Qiu, Xue Cai, Yang Yuan, Bo Xie, Zilin Sun, Tongzhi Wu
    Diabetes Research and Clinical Practice.2022; 189: 109939.     CrossRef
  • Research Progress of Body Composition Changes in Type 2 Diabetes Patients
    鹏霞 张
    Advances in Clinical Medicine.2022; 12(08): 7181.     CrossRef
  • Associations of eating speed with fat distribution and body shape vary in different age groups and obesity status
    Saili Ni, Menghan Jia, Xuemiao Wang, Yun Hong, Xueyin Zhao, Liang Zhang, Yuan Ru, Fei Yang, Shankuan Zhu
    Nutrition & Metabolism.2022;[Epub]     CrossRef
  • Body composition, trabecular bone score and vertebral fractures in subjects with Klinefelter syndrome
    W. Vena, F. Carrone, A. Delbarba, O. Akpojiyovbi, L. C. Pezzaioli, P. Facondo, C. Cappelli, L. Leonardi, L. Balzarini, D. Farina, A. Pizzocaro, A. G. Lania, G. Mazziotti, A. Ferlin
    Journal of Endocrinological Investigation.2022; 46(2): 297.     CrossRef
  • Genetically predicted body fat mass and distribution with diabetic kidney disease: A two-sample Mendelian randomization study
    Min Wang, Xin Li, Hang Mei, Zhao-Hui Huang, Yue Liu, Yong-Hong Zhu, Tian-Kui Ma, Qiu-Ling Fan
    Frontiers in Genetics.2022;[Epub]     CrossRef
  • Screening for Prediabetes and Diabetes in Korean Nonpregnant Adults: A Position Statement of the Korean Diabetes Association, 2022
    Kyung Ae Lee, Dae Jung Kim, Kyungdo Han, Suk Chon, Min Kyong Moon
    Diabetes & Metabolism Journal.2022; 46(6): 819.     CrossRef
  • Age- and Sex-Related Differential Associations between Body Composition and Diabetes Mellitus
    Eun Roh, Soon Young Hwang, Jung A Kim, You-Bin Lee, So-hyeon Hong, Nam Hoon Kim, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo
    Diabetes & Metabolism Journal.2021; 45(2): 183.     CrossRef
  • Neck circumference and metabolic syndrome: A cross-sectional population-based study
    Hooman Ebrahimi, Payam Mahmoudi, Farhad Zamani, Sedighe Moradi
    Primary Care Diabetes.2021; 15(3): 582.     CrossRef
  • Development of a clinical risk score for incident diabetes: A 10‐year prospective cohort study
    Tae Jung Oh, Jae Hoon Moon, Sung Hee Choi, Young Min Cho, Kyong Soo Park, Nam H Cho, Hak Chul Jang
    Journal of Diabetes Investigation.2021; 12(4): 610.     CrossRef
  • The association of glucocorticoid receptor polymorphism with metabolic outcomes in menopausal women with adrenal incidentalomas
    Sanja Ognjanović, Jadranka Antić, Tatjana Pekmezović, Bojana Popović, Tatjana Isailović, Ivana Božić Antić, Tamara Bogavac, Valentina Elezović Kovačević, Dušan Ilić, Milica Opalić, Djuro Macut
    Maturitas.2021; 151: 15.     CrossRef
  • Distinct opposing associations of upper and lower body fat depots with metabolic and cardiovascular disease risk markers
    Mahasampath Gowri S, Belavendra Antonisamy, Finney S. Geethanjali, Nihal Thomas, Felix Jebasingh, Thomas V. Paul, Fredrik Karpe, Clive Osmond, Caroline H. D. Fall, Senthil K. Vasan
    International Journal of Obesity.2021; 45(11): 2490.     CrossRef
  • Body Roundness Index Is a Superior Obesity Index in Predicting Diabetes Risk Among Hypertensive Patients: A Prospective Cohort Study in China
    Yingshan Liu, Xiaocong Liu, Haixia Guan, Shuting Zhang, Qibo Zhu, Xiaoying Fu, Hongmei Chen, Songtao Tang, Yingqing Feng, Jian Kuang
    Frontiers in Cardiovascular Medicine.2021;[Epub]     CrossRef
  • Subcutaneous adipose tissue distribution and serum lipid/lipoprotein in unmedicated postmenopausal women: A B-mode ultrasound study

    Imaging.2021; 13(2): 119.     CrossRef
  • The Leg Fat to Total Fat Ratio Is Associated with Lower Risks of Non-Alcoholic Fatty Liver Disease and Less Severe Hepatic Fibrosis: Results from Nationwide Surveys (KNHANES 2008–2011)
    Hyun Min Kim, Yong-ho Lee
    Endocrinology and Metabolism.2021; 36(6): 1232.     CrossRef
  • Optimal Cut-Offs of Body Mass Index and Waist Circumference to Identify Obesity in Chinese Type 2 Diabetic Patients


    Qinying Zhao, Xiangjun Chen, Jinshan Wu, Lilin Gong, Jinbo Hu, Shumin Yang, Qifu Li, Zhihong Wang
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 1899.     CrossRef
  • Weight Loss after 12 Weeks of Exercise and/or Nutritional Guidance Is Not Obligatory for Induced Changes in Local Fat/Lean Mass Indexes in Adults with Excess of Adiposity
    Robinson Ramírez-Vélez, Mikel Izquierdo, Karem Castro-Astudillo, Carolina Medrano-Mena, Angela Liliana Monroy-Díaz, Rocío del Pilar Castellanos-Vega, Héctor Reynaldo Triana-Reina, María Correa-Rodríguez
    Nutrients.2020; 12(8): 2231.     CrossRef
  • VISCERAL FAT, PHYSICAL FITNESS AND BIOCHEMICAL MARKERS OF BRAZILIAN MILITARY PERSONNEL
    Laércio Camilo Rodrigues, Marcos de Sá Rego Fortes, Marco Antônio Muniz Lippert, Samir Ezequiel Da Rosa, José Fernandes Filho
    Revista Brasileira de Medicina do Esporte.2020; 26(1): 21.     CrossRef
  • Comparison of 7-site skinfold measurement and dual-energy X-ray absorptiometry for estimating body fat percentage and regional adiposity in Taiwanese diabetic patients
    Feng-Chih Kuo, Chieh-Hua Lu, Li-Wei Wu, Tung-Wei Kao, Sheng-Chiang Su, Jhih-Syuan Liu, Kuan-Chan Chen, Chia-Hao Chang, Chih-Chun Kuo, Chien-Hsing Lee, Chang-Hsun Hsieh, Mauro Lombardo
    PLOS ONE.2020; 15(7): e0236323.     CrossRef
  • Outcomes specific to patient sex after open ventral hernia repair
    Kathryn A. Schlosser, Sean R. Maloney, Otto Thielan, Tanushree Prasad, Kent Kercher, Paul D. Colavita, B Todd Heniford, Vedra A. Augenstein
    Surgery.2020; 167(3): 614.     CrossRef
  • Age-Related Changes in Body Composition and Bone Mineral Density and Their Relationship with the Duration of Diabetes and Glycaemic Control in Type 2 Diabetes


    Ying Tang, Lilin Gong, Xiangjun Chen, Zhipeng Du, Jinbo Hu, Zhixin Xu, Jinshan Wu, Qifu Li, Zhihong Wang
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 4699.     CrossRef
  • Lipodystrophy: A paradigm for understanding the consequences of "overloading" adipose tissue
    Koini Lim, Afreen Haider, Claire Adams, Alison Sleigh, David Savage
    Physiological Reviews.2020;[Epub]     CrossRef
  • Premeal Consumption of a Protein-Enriched, Dietary Fiber-Fortified Bar Decreases Total Energy Intake in Healthy Individuals
    Chang Ho Ahn, Jae Hyun Bae, Young Min Cho
    Diabetes & Metabolism Journal.2019; 43(6): 879.     CrossRef
  • Differences in dietary intakes, body compositions, and biochemical indices between metabolically healthy and metabolically abnormal obese Korean women
    Eun Yeong Kang, Jung-Eun Yim
    Nutrition Research and Practice.2019; 13(6): 488.     CrossRef
  • The Association between Body Composition using Dual energy X-ray Absorptiometry and Type-2 Diabetes: A Systematic Review and Meta-Analysis of Observational studies
    Preeti Gupta, Carla Lanca, Alfred T. L. Gan, Pauline Soh, Sahil Thakur, Yijin Tao, Neelam Kumari, Ryan E. K. Man, Eva K. Fenwick, Ecosse L. Lamoureux
    Scientific Reports.2019;[Epub]     CrossRef
  • Genes that make you fat, but keep you healthy
    R. J. F. Loos, T. O. Kilpeläinen
    Journal of Internal Medicine.2018; 284(5): 450.     CrossRef
  • Overview of Epidemiology and Contribution of Obesity and Body Fat Distribution to Cardiovascular Disease: An Update
    Marie-Eve Piché, Paul Poirier, Isabelle Lemieux, Jean-Pierre Després
    Progress in Cardiovascular Diseases.2018; 61(2): 103.     CrossRef
  • Relevance of human fat distribution on lipid and lipoprotein metabolism and cardiovascular disease risk
    Marie-Eve Piché, Senthil K. Vasan, Leanne Hodson, Fredrik Karpe
    Current Opinion in Lipidology.2018; 29(4): 285.     CrossRef
  • Comparison of regional fat measurements by dual-energy X-ray absorptiometry and conventional anthropometry and their association with markers of diabetes and cardiovascular disease risk
    S K Vasan, C Osmond, D Canoy, C Christodoulides, M J Neville, C Di Gravio, C H D Fall, F Karpe
    International Journal of Obesity.2018; 42(4): 850.     CrossRef
Diabetes Epidemics in Korea: Reappraise Nationwide Survey of Diabetes "Diabetes in Korea 2007"
Ie Byung Park, Jaiyong Kim, Dae Jung Kim, Choon Hee Chung, Jee-Young Oh, Seok Won Park, Juneyoung Lee, Kyung Mook Choi, Kyung Wan Min, Jeong Hyun Park, Hyun Shik Son, Chul Woo Ahn, Hwayoung Kim, Sunhee Lee, Im Bong Lee, Injeoung Choi, Sei Hyun Baik
Diabetes Metab J. 2013;37(4):233-239.   Published online August 14, 2013
DOI: https://doi.org/10.4093/dmj.2013.37.4.233
  • 5,322 View
  • 59 Download
  • 62 Crossref
AbstractAbstract PDFPubReader   

There are many studies on the prevalence, clinical characteristics, and economic burden of diabetes across the past four decades in Korea. Nonetheless, there is a dearth of nationwide study regarding diabetes encompassing all age group. Eight years ago, the Committee on the Epidemiology of Diabetes Mellitus of Korean Diabetes Association collaborated with Health Insurance Review & Assessment Service to evaluate the status of diabetes care and characteristics in diabetic patients in Korea. In 2007, the collaborative task force team published a comprehensive survey titled "Diabetes in Korea 2007." In this review, we reappraise the diabetic epidemics from the joint report and suggest further studies that are needed to be investigated in the future.

Citations

Citations to this article as recorded by  
  • Revisiting the Diabetes Crisis in Korea: Call for Urgent Action
    Jun Sung Moon
    The Journal of Korean Diabetes.2023; 24(1): 1.     CrossRef
  • Risk assessment and classification for foot ulceration among patients with type 2 diabetes in South Korea
    Eun Joo Lee, Ihn Sook Jeong, In Ju Kim, Young Hye Cho, Yun Jin Kim
    International Journal of Nursing Practice.2022;[Epub]     CrossRef
  • Using real-world data for supporting regulatory decision making: Comparison of cardiovascular and safety outcomes of an empagliflozin randomized clinical trial versus real-world data
    Ha Young Jang, In-Wha Kim, Jung Mi Oh
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Differences in health behavior and nutrient intake status between diabetes-aware and unaware Korean adults based on the Korea national health and nutrition examination survey 2016–18 data: A cross-sectional study
    Anshul Sharma, Chen Lulu, Kee-Ho Song, Hae-Jeung Lee
    Frontiers in Public Health.2022;[Epub]     CrossRef
  • Do statins benefit low-risk population for primary prevention of atherosclerotic cardiovascular disease: A retrospective cohort study
    In Sun Ryou, Ju Young Kim, Hwa Yeon Park, Sohee Oh, Sehun Kim, Hwa Jung Kim
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • Association between oseltamivir use and neuropsychiatric adverse events in influenza patients: a nationwide population-based cohort study
    Hye-Rim Kang, Suk-Chan Jang, Ju-Young Shin
    Expert Opinion on Drug Safety.2021; 20(2): 245.     CrossRef
  • Effectiveness and safety of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in older adults with type 2 diabetes: A nationwide population‐based study
    Seung Jin Han, Kyoung Hwa Ha, Nami Lee, Dae Jung Kim
    Diabetes, Obesity and Metabolism.2021; 23(3): 682.     CrossRef
  • Cost-Effectiveness of Tiotropium in Elderly Patients with Severe Asthma Using Real-World Data
    Sung-Hyun Hong, Jeong-Yeon Cho, Tae-Bum Kim, Eui-Kyung Lee, Sun-Hong Kwon, Ju-Young Shin
    The Journal of Allergy and Clinical Immunology: In Practice.2021; 9(5): 1939.     CrossRef
  • Dapagliflozin improves cardiovascular risk factors in Emirati patients with T2DM
    Aml Mohamed Nada, Mariam Adel Younan
    Therapeutic Advances in Endocrinology and Metabolism.2021; 12: 204201882199536.     CrossRef
  • Association between socioeconomic position and diabetic foot ulcer outcomes: a population-based cohort study in South Korea
    Jeong Hyun Ha, Heejin Jin, Ji-Ung Park
    BMC Public Health.2021;[Epub]     CrossRef
  • Etiology, diagnosis, complications, and treatments of diabetic foot
    Dong-Kyo Seo
    Journal of the Korean Medical Association.2021; 64(8): 523.     CrossRef
  • Hospital admissions due to endocrine diseases in Korean male firefighters
    Seunghoon Ryu, Yong-Jin Lee, Eun-Chul Jang, Soon-Chan Kwon, KiSeok Kim, Yeon-Soon Ahn, Young-Sun Min
    Annals of Occupational and Environmental Medicine.2021;[Epub]     CrossRef
  • Association between Frequency of Breakfast Consumption and Insulin Resistance Using Triglyceride-Glucose Index: A Cross-Sectional Study of the Korea National Health and Nutrition Examination Survey (2016–2018)
    Hye Jin Joo, Gyu Ri Kim, Eun-Cheol Park, Sung-In Jang
    International Journal of Environmental Research and Public Health.2020; 17(9): 3322.     CrossRef
  • Review of Diabetic Foot Complication Assessment Tools Developed from 2007 to 2016
    Yoonhee Lee, Youngshin Song
    Journal of Korean Academy of Fundamentals of Nursing.2019; 26(4): 231.     CrossRef
  • Associations between Breastfeeding and Type 2 Diabetes Mellitus and Glycemic Control in Parous Women: A Nationwide, Population-Based Study
    Ga Eun Nam, Kyungdo Han, Do-Hoon Kim, Youn Huh, Byoungduck Han, Sung Jung Cho, Yong Gyu Park, Yong-Moon Park
    Diabetes & Metabolism Journal.2019; 43(2): 236.     CrossRef
  • Risk of osteoporosis in patients with chronic inflammatory neuropathy- a population-based cohort study
    Seung Woo Kim, Eun Hwa Kim, Jinae Lee, Young-Chul Choi, Seung Min Kim, Ha Young Shin
    Scientific Reports.2019;[Epub]     CrossRef
  • Differences in the risk of mood disorders in patients with asthma-COPD overlap and in patients with COPD alone: a nationwide population-based retrospective cohort study in Korea
    Hye-Rim Kang, Sung-Hyun Hong, So-Young Ha, Tae-Bum Kim, Eui-Kyung Lee
    Respiratory Research.2019;[Epub]     CrossRef
  • A Comparison of Leukotriene Receptor Antagonists to Low-Dose Inhaled Corticosteroids in the Elderly with Mild Asthma
    Sung-Hyun Hong, Hye-Rim Kang, Jin Hyun Nam, Sun-Kyeong Park, Tae-Bum Kim, Eui-Kyung Lee
    The Journal of Allergy and Clinical Immunology: In Practice.2019; 7(8): 2642.     CrossRef
  • The Need to Improve the Quality of Diabetes Care in Korea
    Seung Jin Han, Dae Jung Kim
    Journal of Korean Medical Science.2019;[Epub]     CrossRef
  • Fifty Years of Compassionate Care and Harmonious Collaboration of the Korean Diabetes Association: The 50th Anniversary of Korean Diabetes Association
    Jong Chul Won, Eun-Jung Rhee, Hyung Joon Yoo
    Diabetes & Metabolism Journal.2018; 42(6): 475.     CrossRef
  • Depth and combined infection is important predictor of lower extremity amputations in hospitalized diabetic foot ulcer patients
    Eun-Gyo Jeong, Sung Shim Cho, Sang-Hoon Lee, Kang-Min Lee, Seo-Kyung Woo, Yoongoo Kang, Jae-Seung Yun, Seon-Ah Cha, Yoon-Jung Kim, Yu-Bae Ahn, Seung-Hyun Ko, Jung-Min Lee
    The Korean Journal of Internal Medicine.2018; 33(5): 952.     CrossRef
  • Favorable glycemic response after pancreatoduodenectomy in both patients with pancreatic cancer and patients with non-pancreatic cancer
    Seo Young Sohn, Eun Kyung Lee, Sung-Sik Han, You Jin Lee, Yul Hwangbo, Young Hwa Kang, Seung Duk Lee, Seong Hoon Kim, Sang Myung Woo, Woo Jin Lee, Eun Kyung Hong, Sang-Jae Park
    Medicine.2018; 97(18): e0590.     CrossRef
  • Clinical Importance of Diabetic Neuropathy
    Tae Sun Park
    The Journal of Korean Diabetes.2018; 19(3): 147.     CrossRef
  • Women are less likely than men to achieve optimal glycemic control after 1 year of treatment: A multi-level analysis of a Korean primary care cohort
    Seung-Ah Choe, Joo Yeong Kim, Young Sun Ro, Sung-Il Cho, Antonio Palazón-Bru
    PLOS ONE.2018; 13(5): e0196719.     CrossRef
  • Diagnosis and Management of Diabetic Foot
    Chang Won Lee
    The Journal of Korean Diabetes.2018; 19(3): 168.     CrossRef
  • HbA1c Cutoff for Prediabetes and Diabetes Based on Oral Glucose Tolerance Test in Obese Children and Adolescents
    Hyo-Kyoung Nam, Won Kyoung Cho, Jae Hyun Kim, Young-Jun Rhie, Sochung Chung, Kee-Hyoung Lee, Byung-Kyu Suh
    Journal of Korean Medical Science.2018;[Epub]     CrossRef
  • Diabetes Fact Sheet in Korea, 2016: An Appraisal of Current Status
    Jong Chul Won, Jae Hyuk Lee, Jae Hyeon Kim, Eun Seok Kang, Kyu Chang Won, Dae Jung Kim, Moon-Kyu Lee
    Diabetes & Metabolism Journal.2018; 42(5): 415.     CrossRef
  • Risk factors of asthma exacerbation based on asthma severity: a nationwide population-based observational study in South Korea
    Hye-Rim Kang, Hyun Jin Song, Jin Hyun Nam, Sung-Hyun Hong, So-Young Yang, SangEun Ju, Sang Won Lee, Tae-Bum Kim, Hye-Lin Kim, Eui-Kyung Lee
    BMJ Open.2018; 8(3): e020825.     CrossRef
  • Foot Care for Diabetic Patients
    Hye Jung Cha
    The Journal of Korean Diabetes.2018; 19(1): 41.     CrossRef
  • Risk of new-onset diabetes among patients treated with statins according to hypertension and gender: Results from a nationwide health-screening cohort
    Sang-Eun Lee, Ji Min Sung, In-Jeong Cho, Hyeon Chang Kim, Hyuk-Jae Chang, Lamberto Manzoli
    PLOS ONE.2018; 13(4): e0195459.     CrossRef
  • Treatment variation related to comorbidity and complications in type 2 diabetes
    Yeon Young Cho, Sung-il Cho
    Medicine.2018; 97(37): e12435.     CrossRef
  • Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus
    Hyun A Cho, Young Lee Jung, Yong Hoon Lee, Yu Chang Lee, Jung Eun Lee, Sol Jae Lee, Su Jin Jeong, Chong Hwa Kim
    Journal of Obesity & Metabolic Syndrome.2017; 26(2): 107.     CrossRef
  • Physician-Directed Diabetes Education without a Medication Change and Associated Patient Outcomes
    Hun-Sung Kim, Hyunah Kim, Hae-Kyung Yang, Eun Young Lee, Yoo Jin Jeong, Tong Min Kim, So Jung Yang, Seo Yeon Baik, Seung-Hwan Lee, Jae Hyoung Cho, In Young Choi, Hyeon Woo Yim, Bong-Yun Cha
    Diabetes & Metabolism Journal.2017; 41(3): 187.     CrossRef
  • Current status of managing diabetes mellitus in Korea
    Kyoung Hwa Ha, Dae Jung Kim
    The Korean Journal of Internal Medicine.2016; 31(5): 845.     CrossRef
  • 7th Asian PAD Workshop

    Annals of Vascular Diseases.2016; 9(2): 135.     CrossRef
  • Trends in Diabetes Incidence in the Last Decade Based on Korean National Health Insurance Claims Data
    Sun Ok Song, Yong-ho Lee, Dong Wook Kim, Young Duk Song, Joo Young Nam, Kyoung Hye Park, Dae Jung Kim, Seok Won Park, Hyun Chul Lee, Byung-Wan Lee
    Endocrinology and Metabolism.2016; 31(2): 292.     CrossRef
  • Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002–2013
    Seung-Hyun Ko, Dae-Jung Kim, Jong-Heon Park, Cheol-Young Park, Chang Hee Jung, Hyuk-Sang Kwon, Joong-Yeol Park, Kee-Ho Song, Kyungdo Han, Ki-Up Lee, Kyung-Soo Ko
    Medicine.2016; 95(27): e4018.     CrossRef
  • Glycosylated Hemoglobin Threshold for Predicting Diabetes and Prediabetes from the Fifth Korea National Health and Nutrition Examination Survey
    Sangmo Hong, Jun Goo Kang, Chul Sik Kim, Seong Jin Lee, Cheol-Young Park, Chang Beom Lee, Sung-Hee Ihm
    Diabetes & Metabolism Journal.2016; 40(2): 167.     CrossRef
  • Predictive Value of Glucose Parameters Obtained From Oral Glucose Tolerance Tests in Identifying Individuals at High Risk for the Development of Diabetes in Korean Population
    Hae Kyung Yang, Hee-Sung Ha, Marie Rhee, Jin-Hee Lee, Yong-Moon Park, Hyuk-Sang Kwon, Hyeon-Woo Yim, Moo-Il Kang, Won-Chul Lee, Ho-Young Son, Seung-Hwan Lee, Kun-Ho Yoon
    Medicine.2016; 95(10): e3053.     CrossRef
  • Serum preadipocyte factor 1 concentrations and risk of developing diabetes: a nested case–control study
    S. H. Lee, M. Rhee, H. K. Yang, H. S. Ha, J. H. Lee, H. S. Kwon, Y. M. Park, H. W. Yim, M. I. Kang, W. C. Lee, H. Y. Son, K. H. Yoon
    Diabetic Medicine.2016; 33(5): 631.     CrossRef
  • Is an Oral Glucose Tolerance Test Still Valid for Diagnosing Diabetes Mellitus?
    Dong-Lim Kim, Sun-Doo Kim, Suk Kyeong Kim, Sooyoun Park, Kee-Ho Song
    Diabetes & Metabolism Journal.2016; 40(2): 118.     CrossRef
  • Fasting plasma glucose concentrations for specified HbA1c goals in Korean populations: data from the Fifth Korea National Health and Nutrition Examination Survey (KNHANES V-2, 2011)
    Sangmo Hong, Jun Goo Kang, Chul Sik Kim, Seong Jin Lee, Chang Beom Lee, Sung-Hee Ihm
    Diabetology & Metabolic Syndrome.2016;[Epub]     CrossRef
  • Combined use of basal insulin analog and acarbose reduces postprandial glucose in patients with uncontrolled type 2 diabetes
    Ji‐Hyun Kim, Ji‐Hyun Ahn, Soo‐Kyung Kim, Dae‐Ho Lee, Hye‐Soon Kim, Ho‐Sang Shon, Hyun‐Jeong Jeon, Tae‐Hwa Kim, Yong‐Wook Cho, Jae‐Taek Kim, Sung‐Min Han, Choon‐Hee Chung, Ohk‐Hyun Ryu, Jae‐Min Lee, Soon‐Hee Lee, Min‐Jeong Kwon, Tae‐kyun Kim, Il‐Seong Namg
    Journal of Diabetes Investigation.2015; 6(2): 219.     CrossRef
  • Anti-Oxidative and Anti-Diabetic Effects of Methanol Extracts from Medicinal Plants
    Youn Ri Lee, Nara Yoon
    Journal of the Korean Society of Food Science and Nutrition.2015; 44(5): 681.     CrossRef
  • Associations Between the Continuity of Ambulatory Care of Adult Diabetes Patients in Korea and the Incidence of Macrovascular Complications
    Young-Hoon Gong, Seok-Jun Yoon, Hyeyoung Seo, Dongwoo Kim
    Journal of Preventive Medicine and Public Health.2015; 48(4): 188.     CrossRef
  • Statin eligibility and cardiovascular risk burden assessed by coronary artery calcium score: Comparing the two guidelines in a large Korean cohort
    Eun-Jung Rhee, Se Eun Park, Hyung Geun Oh, Cheol-Young Park, Ki-Won Oh, Sung-Woo Park, Ron Blankstein, Jorge Plutzky, Won-Young Lee
    Atherosclerosis.2015; 240(1): 242.     CrossRef
  • Evaluation of low-dose aspirin for primary prevention of ischemic stroke among patients with diabetes: a retrospective cohort study
    Ye-Jee Kim, Nam-Kyong Choi, Mi-Sook Kim, Joongyub Lee, Yoosoo Chang, Jong-Mi Seong, Sun-Young Jung, Ju-Young Shin, Ji-Eun Park, Byung-Joo Park
    Diabetology & Metabolic Syndrome.2015;[Epub]     CrossRef
  • Health-Related Quality of Life in Coronary Heart Disease in Korea
    Hyung Tak Lee, Jinho Shin, Young-Hyo Lim, Kyung Soo Kim, Soon Gil Kim, Jeong Hyun Kim, Heon Kil Lim
    Angiology.2015; 66(4): 326.     CrossRef
  • Seroepidemiology of varicella-zoster virus in Korean adolescents and adults using fluorescent antibody to membrane antigen test
    S. B. HAN, K. R. KANG, D. H. HUH, H. C. LEE, J. H. KIM, J. H. KANG, S. H. MA
    Epidemiology and Infection.2015; 143(8): 1643.     CrossRef
  • Changing Clinical Characteristics according to Insulin Resistance and Insulin Secretion in Newly Diagnosed Type 2 Diabetic Patients in Korea
    Jang Won Son, Cheol-Young Park, Sungrae Kim, Han-Kyu Lee, Yil-Seob Lee
    Diabetes & Metabolism Journal.2015; 39(5): 387.     CrossRef
  • Age- and Sex-Specific Relationships between Household Income, Education, and Diabetes Mellitus in Korean Adults: The Korea National Health and Nutrition Examination Survey, 2008-2010
    So-Ra Kim, Kyungdo Han, Jin-Young Choi, Jennifer Ersek, Junxiu Liu, Sun-Jin Jo, Kang-Sook Lee, Hyeon Woo Yim, Won-Chul Lee, Yong Gyu Park, Seung-Hwan Lee, Yong-Moon Park, C. Mary Schooling
    PLOS ONE.2015; 10(1): e0117034.     CrossRef
  • Association between Diabetes Education Status and Clinical Outcomes of Patients with Diabetes Mellitus: Analysis of the Fifth Korea National Health and Nutrition Examination Survey (KNHANES V)
    Jun Sung Kwon, Won Jun Kim, Yang Hee Han, Hyun Joong Kim, Sa Young Shin, Kyoo Ho Choi, Jae Hyuck Jun, Myoung Sook Shim, Jin Yeob Kim
    The Journal of Korean Diabetes.2014; 15(4): 236.     CrossRef
  • The Incidence and Prevalence of Diabetes Mellitus and Related Atherosclerotic Complications in Korea: A National Health Insurance Database Study
    Bo Kyung Koo, Chang-Hoon Lee, Bo Ram Yang, Seung-sik Hwang, Nam-Kyong Choi, Mohammad Ebrahim Khamseh
    PLoS ONE.2014; 9(10): e110650.     CrossRef
  • Current Status of Glycemic Control of Patients with Diabetes in Korea: The Fifth Korea National Health and Nutrition Examination Survey
    Ja Young Jeon, Dae Jung Kim, Seung-Hyun Ko, Hyuk-Sang Kwon, Soo Lim, Sung Hee Choi, Chul Sik Kim, Jee Hyun An, Nan Hee Kim, Jong Chul Won, Jae Hyeon Kim, Bong-Yun Cha, Kee-Ho Song
    Diabetes & Metabolism Journal.2014; 38(3): 197.     CrossRef
  • Strong correlation between glycaemic variability and total glucose exposure in type 2 diabetes is limited to subjects with satisfactory glycaemic control
    S. Suh, J.Y. Joung, S.M. Jin, M.Y. Kim, J.C. Bae, H.D. Park, M.S. Lee, M.K. Lee, J.H. Kim
    Diabetes & Metabolism.2014; 40(4): 272.     CrossRef
  • Current Status of Diabetic Peripheral Neuropathy in Korea: Report of a Hospital-Based Study of Type 2 Diabetic Patients in Korea by the Diabetic Neuropathy Study Group of the Korean Diabetes Association
    Jong Chul Won, Sang Soo Kim, Kyung Soo Ko, Bong-Yun Cha
    Diabetes & Metabolism Journal.2014; 38(1): 25.     CrossRef
  • Impact of Age at First Childbirth on Glucose Tolerance Status in Postmenopausal Women: The 2008–2011 Korean National Health and Nutrition Examination Survey
    Jin Hwa Kim, Yun Jung, Sang Yong Kim, Hak Yeon Bae
    Diabetes Care.2014; 37(3): 671.     CrossRef
  • Predicting the Development of Diabetes Using the Product of Triglycerides and Glucose: The Chungju Metabolic Disease Cohort (CMC) Study
    Seung-Hwan Lee, Hyuk-Sang Kwon, Yong-Moon Park, Hee-Sung Ha, Seung Hee Jeong, Hae Kyung Yang, Jin-Hee Lee, Hyeon-Woo Yim, Moo-Il Kang, Won-Chul Lee, Ho-Young Son, Kun-Ho Yoon, Maria Eugenia Saez
    PLoS ONE.2014; 9(2): e90430.     CrossRef
  • Relationship between socioeconomic status and type 2 diabetes: results from Korea National Health and Nutrition Examination Survey (KNHANES) 2010-2012
    J. Hwang, C. Shon
    BMJ Open.2014; 4(8): e005710.     CrossRef
  • Diabetes Mellitus and Osteoporosis
    Kyoung Min Kim
    The Journal of Korean Diabetes.2013; 14(4): 186.     CrossRef
  • Study on the Correlation between the Nutrient Intakes and Clinical Indices of Type 2 Diabetes Patients
    Ji-Young Kwon, Hae-Yun Chung
    The Korean Journal of Food And Nutrition.2013; 26(4): 909.     CrossRef
  • Role of Sarcopenia in Diabetes Mellitus
    Sang Youl Rhee
    The Journal of Korean Diabetes.2013; 14(4): 178.     CrossRef
Role of HbA1c in the Screening of Diabetes Mellitus in a Korean Rural Community
Jae Hyun Kim, Gun Woo Kim, Mi Young Lee, Jang Yel Shin, Young Goo Shin, Sang Baek Koh, Choon Hee Chung
Diabetes Metab J. 2012;36(1):37-42.   Published online February 17, 2012
DOI: https://doi.org/10.4093/dmj.2012.36.1.37
  • 3,727 View
  • 33 Download
  • 11 Crossref
AbstractAbstract PDFPubReader   
Background

Recently, the measurement of glycated hemoglobin (HbA1c) was recommended as an alternative to fasting plasma glucose or oral glucose tolerance tests for diagnosing diabetes mellitus (DM). In this study, we analyzed HbA1c levels for diabetes mellitus screening in a Korean rural population.

Methods

We analyzed data from 10,111 subjects from a Korean Rural Genomic Cohort study and generated a receiver operating characteristic curve to determine an appropriate HbA1c cutoff value for diabetes.

Results

The mean age of the subjects was 56.3±8.1 years. Fasting plasma glucose and 2-hour plasma glucose after 75 g oral glucose tolerance tests were 97.5±25.6 and 138.3±67.1 mg/dL, respectively. The mean HbA1c level of the subjects was 5.7±0.9%. There were 8,809 non-DM patients (87.1%) and 1,302 DM patients (12.9%). A positive relationship between HbA1c and plasma glucose levels and between HbA1c and 2-hour plasma glucose levels after oral glucose tolerance tests was found in a scatter plot of the data. Using Youden's index, the proper cutoff level of HbA1c for diabetes mellitus screening was 5.95% (sensitivity, 77%; specificity, 89.4%).

Conclusion

Our results suggest that the optimal HbA1c level for DM screening is 5.95%.

Citations

Citations to this article as recorded by  
  • Hyperinsulinemia: an early biomarker of metabolic dysfunction
    Rama A. Vaidya, Sharvari Desai, Panchali Moitra, Sheryl Salis, Shubhada Agashe, Rekha Battalwar, Anushree Mehta, Jagmeet Madan, Soumik Kalita, Shobha A. Udipi, Ashok B. Vaidya
    Frontiers in Clinical Diabetes and Healthcare.2023;[Epub]     CrossRef
  • A Novel Earwax Method to Measure Acute and Chronic Glucose Levels
    Andrés Herane-Vives, Susana Espinoza, Rodrigo Sandoval, Lorena Ortega, Luis Alameda, Allan H. Young, Danilo Arnone, Alexander Hayes, Jan Benöhr
    Diagnostics.2020; 10(12): 1069.     CrossRef
  • Risk Factors for Underdiagnosis of Diabetes Based on the Korean National Health and Nutrition Examination Survey 2013-2015
    Deulle Min, Eunhee Cho
    Asia Pacific Journal of Public Health.2019; 31(5): 404.     CrossRef
  • Recent advances of medical journals in Korea and and further development strategies: Is it possible for them to publish Nobel Prize-winning research?
    Sun Huh
    Journal of the Korean Medical Association.2018; 61(9): 524.     CrossRef
  • The clinical value of HbA1c in combination with FPG in the early screening of the elderly with type 2 diabetes
    Lihua Liu, Wenqing Chen, Minghua Dong, Lixia Jiang, Wei Qiu, Jian Li, Xiaoting Luo, Zhengchun Huang, Qin Wu, Qinfeng Wu, Shuiqin Chen, Lu Ou-Yang, Shumei Li, J.Q. Cheng, H.L. Moffitt, I. Kim, Z.T. Chi, J. Zhang
    BIO Web of Conferences.2017; 8: 01030.     CrossRef
  • The Cutoff Value of HbA1c in Predicting Diabetes and Impaired Fasting Glucose
    Seyoung Kwon, Youngak Na
    The Korean Journal of Clinical Laboratory Science.2017; 49(2): 114.     CrossRef
  • Performance of HbA1c for the prediction of diabetes in a rural community in Korea
    B. M. Song, H. C. Kim, J. Y. Lee, J.‐M. Lee, D. J. Kim, Y.‐H. Lee, I. Suh
    Diabetic Medicine.2015; 32(12): 1602.     CrossRef
  • The Relationship between BMI and Glycated Albumin to Glycated Hemoglobin (GA/A1c) Ratio According to Glucose Tolerance Status
    Ji Hye Huh, Kwang Joon Kim, Byung-Wan Lee, Dong Wook Kim, Eun Seok Kang, Bong Soo Cha, Hyun Chul Lee, Marta Letizia Hribal
    PLoS ONE.2014; 9(2): e89478.     CrossRef
  • Additional perspectives on chronic kidney disease of unknown aetiology (CKDu) in Sri Lanka – lessons learned from the WHO CKDu population prevalence study
    Jennifer Hoponick Redmon, Myles F Elledge, Donna S Womack, Rajitha Wickremashinghe, Kamani P Wanigasuriya, Roshini J Peiris-John, Joseph Lunyera, Kristin Smith, James H Raymer, Keith E Levine
    BMC Nephrology.2014;[Epub]     CrossRef
  • Diagnostic Efficiency of Hemoglobin A1c for Newly Diagnosed Diabetes and Prediabetes in Community-Based Chinese Adults Aged 40 Years or Older
    Kai Liang, Yu Sun, Wen-juan Li, Xiu-ping Zhang, Cheng-qiao Li, Wei-fang Yang, Ze-qiang Ma, Ai-xia Ma, Hui-zhen Zheng, Jun Song, Peng Lin, Xin-guo Hou, Li Chen
    Diabetes Technology & Therapeutics.2014; 16(12): 853.     CrossRef
  • Diagnostic accuracy of HbA1c in diabetes between Eastern and Western
    Shuang Yan, Siying Liu, Yashuang Zhao, Wencui Zhang, Xiaohui Sun, Jianing Li, Fuli Jiang, Jiaming Ju, Ning Lang, Yingqi Zhang, Weiyu Zhou, Qiang Li
    European Journal of Clinical Investigation.2013; 43(7): 716.     CrossRef
Effects of Spironolactone and Losartan on Diabetic Nephropathy in a Type 2 Diabetic Rat Model
Mi Young Lee, Myoung Sook Shim, Bo Hwan Kim, Soon Won Hong, Ran Choi, Eun Young Lee, Soo Min Nam, Gun Woo Kim, Jang Yel Shin, Young Goo Shin, Choon Hee Chung
Diabetes Metab J. 2011;35(2):130-137.   Published online April 30, 2011
DOI: https://doi.org/10.4093/dmj.2011.35.2.130
  • 3,692 View
  • 64 Download
  • 15 Crossref
AbstractAbstract PDFPubReader   
Background

While there is an evidence that the anti-inflammatory properties of spironolactone can attenuate proteinuria in type 2 diabetes, its effects on vascular endothelial growth factor (VEGF) expression in diabetic nephropathy have not been clearly defined. In this study, we examined the effects of spironolactone, losartan, and a combination of these two drugs on albuminuria, renal VEGF expression, and inflammatory and oxidative stress markers in a type 2 diabetic rat model.

Methods

Thirty-three Otsuka-Long-Evans-Tokushima-Fatty (OLETF) rats were divided into four groups and treated with different medication regimens from weeks 25 to 50; OLETF diabetic controls (n=5), spironolactone-treated (n=10), losartan-treated (n=9), and combination of spironolactone- and losartan-treated (n=9).

Results

At week 50, the albumin-to-creatinine ratio was significantly decreased in the losartan and combination groups compared to the control OLETF group. No decrease was detected in the spironolactone group. There was a significant reduction in renal VEGF, transforming growth factor (TGF)-β, and type IV collagen mRNA levels in the spironolactone- and combination regimen-treated groups. Twenty-four hour urine monocyte chemotactic protein-1 levels were comparable in all four groups but did show a decreasing trend in the losartan and combination regimen groups. Twenty-four hour urine malondialdehyde levels were significantly decreased in the spironolactone- and combination regimen-treated groups.

Conclusion

These results suggest that losartan alone and a combined regimen of spironolactone and losartan could ameliorate albuninuria by reducing renal VEGF expression. Also, simultaneous treatment with spironolactone and losartan may have protective effects against diabetic nephropathy by decreasing TGF-β and type IV collagen expression and by reducing oxidative stress in a type 2 diabetic rat model.

Citations

Citations to this article as recorded by  
  • Tetrahydrocurcumin Add‐On therapy to losartan in a rat model of diabetic nephropathy decreases blood pressure and markers of kidney injury
    Mahyar Khazaeli, Ane C. F. Nunes, Yitong Zhao, Mahziar Khazaali, John Prudente, Nosratola D. Vaziri, Bhupinder Singh, Wei Ling Lau
    Pharmacology Research & Perspectives.2023;[Epub]     CrossRef
  • Type 2 Diabetes Mellitus: Pathogenic Features and Experimental Models in Rodents
    Inessa G. Gvazava, M. V. Karimova, A. V. Vasiliev, E. A. Vorotelyak
    Acta Naturae.2022; 14(3): 57.     CrossRef
  • Role of mineralocorticoid receptor antagonists in kidney diseases
    Vishal Patel, Amit Joharapurkar, Mukul Jain
    Drug Development Research.2021; 82(3): 341.     CrossRef
  • Multi-strain probiotic supplement attenuates streptozotocin-induced type-2 diabetes by reducing inflammation and β-cell death in rats
    Pei-Shan Hsieh, Hsieh-Hsun Ho, Shu Ping Tsao, Shih-Hung Hsieh, Wen-Yang Lin, Jui-Fen Chen, Yi-Wei Kuo, Shin-Yu Tsai, Hui-Yu Huang, Michael W. Greene
    PLOS ONE.2021; 16(6): e0251646.     CrossRef
  • Ocular surface complications in diabetes: The interrelationship between insulin and enkephalin
    Indira Purushothaman, Ian S. Zagon, Joseph W. Sassani, Patricia J. McLaughlin
    Biochemical Pharmacology.2021; 192: 114712.     CrossRef
  • Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
    Daiji Kawanami, Yuichi Takashi, Yoshimi Muta, Naoki Oda, Dai Nagata, Hiroyuki Takahashi, Makito Tanabe
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • Effects of single and dual RAAS blockade therapy on progressive kidney disease transition to CKD in rats
    Devesh Aggarwal, Gaaminepreet Singh
    Naunyn-Schmiedeberg's Archives of Pharmacology.2020; 393(4): 615.     CrossRef
  • Bioactive Agent Discovery from the Natural Compounds for the Treatment of Type 2 Diabetes Rat Model
    Shih-Chun Yang, Ching-Yun Hsu, Wei-Ling Chou, Jia-You Fang, Shih-Yi Chuang
    Molecules.2020; 25(23): 5713.     CrossRef
  • Losartan improves renal function and pathology in obese ZSF-1 rats
    Zhi Su, Deborah Widomski, Arthur Nikkel, Laura Leys, Marian Namovic, Diana Donnelly-Roberts, Murali Gopalakrishnan, Steve McGaraughty
    Journal of Basic and Clinical Physiology and Pharmacology.2018; 29(3): 281.     CrossRef
  • Analyzing polymeric nanofibrous scaffold performances in diabetic animal models for translational chronic wound healing research
    Nowsheen Goonoo, Archana Bhaw-Luximon
    Nanotechnology Reviews.2017; 6(6): 583.     CrossRef
  • Stimulatory effect of insulin on renal proximal tubule sodium transport is preserved in type 2 diabetes with nephropathy
    Motonobu Nakamura, Nobuhiko Satoh, Masashi Suzuki, Haruki Kume, Yukio Homma, George Seki, Shoko Horita
    Biochemical and Biophysical Research Communications.2015; 461(1): 154.     CrossRef
  • Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats
    Amal Hofni, Mohamed A. El-Moselhy, Ashraf Taye, Mohamed M. Khalifa
    European Journal of Pharmacology.2014; 744: 173.     CrossRef
  • Renal Protective Role of Xiexin Decoction with Multiple Active Ingredients Involves Inhibition of Inflammation through Downregulation of the Nuclear Factor-κB Pathway in Diabetic Rats
    Jia-sheng Wu, Rong Shi, Jie Zhong, Xiong Lu, Bing-liang Ma, Tian-ming Wang, Bin Zan, Yue-ming Ma, Neng-neng Cheng, Fu-rong Qiu
    Evidence-Based Complementary and Alternative Medicine.2013; 2013: 1.     CrossRef
  • The use of animal models in diabetes research
    Aileen JF King
    British Journal of Pharmacology.2012; 166(3): 877.     CrossRef
  • Effect of Eplerenone, a Selective Aldosterone Blocker, on the Development of Diabetic Nephropathy in Type 2 Diabetic Rats
    Jae Hee Ahn, Ho Cheol Hong, Myong Jin Cho, Yoon Jung Kim, Hae Yoon Choi, Chai Ryoung Eun, Sae Jeong Yang, Hye Jin Yoo, Hee Young Kim, Ji A Seo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi, Nan Hee Kim
    Diabetes & Metabolism Journal.2012; 36(2): 128.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal